louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01612806: A Multi-center, Prospective, Randomized Study With PriMatrix and PriMatrix Ag for the Treatment of Venous Leg Ulcers
Official title: A Multi-center, Prospective, Randomized Study With PriMatrix Dermal Repair Scaffold, PriMatrix Ag Antimicrobial Dermal Repair Scaffold, and Standard of Care for the Treatment of Venous Leg Ulcers
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Venous Stasis Ulcer
Lead sponsor: Integra LifeSciences Corporation
Sponsor class: INDUSTRY
First posted: 2012-06-06
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the effectiveness of PriMatrix, PriMatrix Ag, and Standard of Care in the treatment of venous leg ulcers (VLUs).

Detailed description: Healing percentages

Eligibility criteria: Inclusion Criteria:

* Men or women ≥ 18 years of age
* Ankle-brachial index (ABI) \> 0.80
* Study wound 2-64 cm2 surface area
* Wound does not exhibit a greater than 50% reduction in surface area during the screening period

Exclusion Criteria:

* Suspected or confirmed signs/symptoms of wound infection
* Hypersensitivity to bovine collagen
* Body Mass Index (BMI) ≥ 45

Primary outcomes:
measure: Percent of VLUs healed by week 12 post-randomization
timeFrame: 12 weeks
Secondary outcomes:
measure: Cost of treatment
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Ponce
country: Puerto Rico
facility: Dr. Pila Metropolitan Hospital Wound Healing Center
city: San Juan
country: Puerto Rico
facility: Caribbean Clinical Trials
city: San Juan
country: Puerto Rico
facility: Doctors' Center Hospital of San Juan
city: San Juan
country: Puerto Rico
facility: Wound and Ulcer Care Clinic of San Juan
city: Vega Baja
country: Puerto Rico
facility: Wilma N. Vazquez Hospital
Study officials:
affiliation: TEI
name: John Starinski, DPM
role: STUDY_DIRECTOR
References:
Clinical trial NCT00708006: A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
Official title: A Phase 1 Dose-Escalation Study to Evaluate the Safety and Tolerability of HGS1029 (AEG40826-2HCl) in Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Advanced Solid Tumors
Lead sponsor: Human Genome Sciences Inc.
Sponsor class: INDUSTRY
First posted: 2008-07-02
Enrollment: 66
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.


Eligibility criteria: Inclusion Criteria:

* Confirmed advanced solid malignancy
* Life expectancy of at least 3 months
* Age 18 years or older
* Acceptable liver function
* Acceptable renal function
* Acceptable hematologic status

Exclusion Criteria:

* Received investigational (not yet approved by a regulatory authority)agent within 4 weeks before enrollment.
* Received non-investigational agent within 3 weeks before enrollment.
* Progressive CNS involvement including the need of corticosteroids
* Pregnant or breast-feeding women
* Active, uncontrolled bacterial, viral, or fungal infections within 2 weeks of Cycle 1 Day 1
* Known HIV infection

Primary outcomes:
measure: To assess the safety and dose-limiting toxicity of HGS1029 administered weekly X 3, repeated every 4 weeks
timeFrame: throughout the study
Secondary outcomes:
measure: Determination of pharmacokinetic profile; evaluation of biomarkers; evaluation of possible anti-tumor activity
timeFrame: throughout the study
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University Dept. of Medicine-Oncology
state: California
city: Aurora
country: United States
facility: University of Colorado Health Sciences Center
state: Colorado
city: Nashville
country: United States
facility: The Sarah Cannon Research Institute
state: Tennessee
Study officials:
affiliation: Human Genome Sciences Inc.
name: Gilles Gallant, B. Pharm.,Ph.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT04082806: Memory Enhancement by Gamma-hydroxybutyrate vs. Trazodone in Major Depressive Disorder.
Official title: Memory Enhancement by Gamma-hydroxybutyrate vs. Trazodone in Major Depressive Disorder.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Major Depressive Disorder
Lead sponsor: Psychiatric University Hospital, Zurich
Sponsor class: OTHER
First posted: 2019-09-09
Enrollment: 54
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: 30 healthy adults and 30 patients with major depressive disorder, will take part in three single-application pharmacological interventions (GHB vs. Trazodone vs. placebo p.o.) to test potential effects of these drugs on nocturnal memory consolidation. All participants will be assessed with mood state questionnaires, tests of emotional, procedural and declarative memory consolidation, polysomnography, EEG and neuroinflammatory biomarkers. At experimental nights, learning tasks are performed prior to sleep. The next morning, recalling tasks are performed. Each subject will pass through 5 study nights (1 screening, 1 adaptation and 3 experimental nights).


Eligibility criteria: Arm 1 (healthy controls):

* Healthy participants,
* Non-smoker,
* Age 20-65 years

Arm 2 (patients with depression):

* Diagnosis of major depression (DSM-V),
* Selective Serotonin-Reuptake-Inhibitor (SSRI) or Selective Serotonin-Noradrenalin-Reuptake-Inhibitor (SSNRI) medication,
* Age 20-65 years

Primary outcomes:
measure: slow wave sleep amount
timeFrame: 1 night
measure: performance in emotional memory consolidation tasks by Emotional Picture Memory Task (EPMT)
timeFrame: 10 hours after encoding
measure: performance in procedural memory consolidation tasks by Finger Sequence-Tapping Task (FSTT)
timeFrame: 10 hours after encoding
measure: performance in declarative memory consolidation tasks by Paired Word List Task (PAWL)
timeFrame: 10 hours after encoding
measure: Blood levels of Brain Derived Neurotrophic Factor (BDNF).
timeFrame: 9 hours after solid drug administration
measure: homeostatic sleep pressure by Psychomotor Vigilance Task
timeFrame: 10 hours after solid drug administration
measure: homeostatic sleep pressure by N-back Task
timeFrame: 10 hours after solid drug administration
Secondary outcomes:
measure: Sleep quality assessed by Morgen Questionionnaire (MQ)
timeFrame: at 8:00 a.m. after experimental night 1,2 and 3
measure: Sleep quality assessed by Karolinska Schläfrigkeitsskala (SKK)
timeFrame: at 8:00 a.m. after experimental night 1,2 and 3
measure: Cortisol Saliva Response (CAR)
timeFrame: 0minutes, 15minutes, 30minutes, 45minutes and 60minutes after awekening
measure: Score on Positive and Negative Affect Schedule (PANAS)
timeFrame: 8 hours after solid drug administration
Other outcomes:
Locations:
city: Zürich
country: Switzerland
facility: Psychiatric University Hospital
state: ZH
Study officials:
References:
Clinical trial NCT00154206: Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Cyclosporine Microemulsion and Steroids in Pediatric de Novo Renal Transplant Patients
Official title: A Multicenter, Open, Single Arm, Pilot Study to Evaluate Efficacy, Tolerability and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion and Steroids in Pediatric de Novo Renal Transplant Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Kidney Transplantation
Keywords: Enteric-coated mycophenolate sodium,
de novo,
renal transplantation,
pediatric
De novo pediatric renal transplantation
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2005-09-12
Enrollment: 15
Sex: ALL
Minimum age (years): 5
Maximum age (years): 16
Standard ages: CHILD
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The aim of this pilot study is to evaluate efficacy and tolerability of EC-MPS b.i.d, with Cyclosporine microemulsion and steroids in pediatric de novo renal transplant patients. Safety and doses variations are also evaluated.


Eligibility criteria: Inclusion Criteria:

* Recipients of a primary renal transplantation
* Recipients of a renal transplantation only

Exclusion Criteria:

* Recipients of a multi-organ transplantation
* Unable to take an oral medication
* Requiring an induction therapy with polyclonal, monoclonal antibodies (OKT3, ATG, ALG).

Other protocol-defined inclusion / exclusion criteria may apply

Primary outcomes:
measure: Incidence of biopsy-proven-acute-rejection and treatment failure (defined by graft loss and/or biopsy-proven-acute-rejection and/or death and/or lost to follow-up and/or study discontinuation) within the 6 and 12 months post transplantation
Secondary outcomes:
measure: Within the 6 and 12 months post transplantation
measure: Incidence of acute rejection resistant to steroids
measure: Incidence of graft loss and death
measure: Renal function by creatinine and creatinine clearance (Schwartz formula)
measure: Incidence of premature study drug discontinuation due to safety reason
measure: Pharmacokinetic profile of Myfortic.
measure: Frequency of adverse events, incidence of clinically notable laboratory abnormalities, and change on vital signs.
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: Novartis
Study officials:
affiliation: Novartis
name: Novartis
role: STUDY_DIRECTOR
References:
citation: Niaudet P, Charbit M, Loirat C, Lapeyraque AL, Tsimaratos M, Cailliez M, Foulard M, Dehennault M, Marquet P, Chaouche-Teyara K, Lemay D. Enteric-coated mycophenolate sodium in de novo pediatric renal transplant patients. Pediatr Nephrol. 2009 Feb;24(2):395-402. doi: 10.1007/s00467-008-1031-7. Epub 2008 Nov 5.
Clinical trial NCT03149406: Study of microRNAs in the Evolution of Carotid Plaque. Physiopathological and Therapeutic Interest
Official title: Study of microRNAs in the Evolution of Carotid Plaque. Physiopathological and Therapeutic Interest
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: miRNAs
Carotid Plaque
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
First posted: 2017-05-11
Enrollment: 245
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Symptomatic patients in the service, and asymptomatic in consultation with carotid atheroma plaque

Brief summary: Carotid stenosis of atherosclerotic origin may be responsible for stroke, which is one of the most important causes of morbidity and mortality in the Western world

Detailed description: Carotid stenosis of atherosclerotic origin may be responsible for stroke, which is one of the most important causes of morbidity and mortality in the Western world. The constitution of the atheroma plaque is linked to the deregulation of several biological phenomena, including angiogenesis, adipogenesis, inflammatory response, lipid metabolism and oxidative stress. In addition to its anatomical and physiological characteristics, the notion of plate stability is of paramount importance for clinical implications. This stability depends largely on the biological composition of the plate. A vulnerable or unstable plaque often has a large lipid body consisting of foam cells (macrophages laden with oxidized LDL) with a thin fibrous screed consisting of smooth muscle cells (CML), collagen fibers and extracellular matrix. This plaque is also made up of numerous inflammatory cells including macrophages, rich vascularization and intraplate hemorrhage. Although the cell composition of the unstable plate is still relatively established, its molecular analysis remains little known.

The benefit of carotid surgery in asymptomatic patients with stenosis greater than 70% is increasingly controversial given the moderate risk of spontaneous stroke under optimal medical treatment. This annual average risk is less than 5%. Thus, the discovery of an original and innovative biomarker, predictive of plate rupture, would define the patients most at risk, who benefit most from this surgery.

Eligibility criteria: Inclusion Criteria:

* Any adult with a carotid thrombo endarterectomy,
* affiliated to a social security scheme,
* informed of the study and not opposed to it.

Exclusion Criteria:

* Any person benefiting from an iterative carotid surgery,
* or refusing to participate in the study,
* or not being able to express its consent.

Primary outcomes:
measure: Analysis of the miRNAs
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens Picardie
state: Picardie
Study officials:
affiliation: CHU AMIENS-PICARDIE
name: Thierry REIX, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04362306: Radiation Oncology Patient Medical Physics Intervention Study
Official title: Radiation Oncology Patient Medical Physics Intervention Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anxiety
Patient Satisfaction
Radiation Therapy
Lead sponsor: The University of Texas Health Science Center at San Antonio
Sponsor class: OTHER
First posted: 2020-04-24
Enrollment: 89
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This investigation is designed to be a two-arm, non-randomized prospective phase 2 study evaluating the impact of medical physicist patient intervention on the anxiety level and patient satisfaction of patients undergoing a course of radiation therapy. The goal is to demonstrate that these interventions will have a significantly positive impact on the overall well-being of the oncology patients.


Eligibility criteria: Inclusion Criteria:

* Age \>/= 18 years
* Patients receiving treatment in the outpatient setting.
* Patients with an Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0, 1, or 2.

Exclusion Criteria:

* Patients receiving a single fraction of treatment.
* History of Prior Radiation.

Primary outcomes:
measure: Anxiety Inventory
timeFrame: Baseline to last treatment (up to 9 weeks)
measure: Patient Satisfaction
timeFrame: Baseline to last treatment (up to 9 weeks)
Secondary outcomes:
measure: Medical competency/health literacy of Spanish speaking patients
timeFrame: Prior to CT simulation
Other outcomes:
Locations:
city: San Antonio
country: United States
facility: Mays Cancer Center, UT Health San Antonio
state: Texas
Study officials:
affiliation: University of Texas
name: Timothy Wagner, MD, MBA
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01813006: Effect of Omega-3 Fatty Acid on Endothelial Function
Official title: Effect of Omega-3 Polyunsaturated Fat on Endothelial Function and Inflammatory Parameters in Familial Hypercholesterolemia - a Double Blind, Placebo-controlled Crossover Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Familial Hypercholesterolemia
Lead sponsor: Nordlandssykehuset HF
Sponsor class: OTHER
Collaborators: name: Pronova BioPharma
First posted: 2013-03-18
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Background

Familial hypercholesterolemia (FH) is an inherited disease in which the level of bad cholesterol (LDL-cholesterol) is increased, leading to an increase in coronary heart disease even if adequately treated with cholesterol lowering medication (statins). Polyunsaturated fatty acids (PUFA) including omega-3 is known to affect the risk for coronary disease, however its effect on patients with FH is not known.

The purpose of the study is to assess the effect of PUFA on patients with FH, with regard to inflammation measured in the blood and the effect on the blood vessels'ability to relax (endothelial function) by means of tonometry.

Hypothesis

Treatment with 4 grams of PUFA a day for 4 months will lead to an improvement in the endothelial function, and the treatment will also lead to a decrease in in several markers of inflammation and in lipids in the blood.


Eligibility criteria: Inclusion Criteria:

* documented familial hypercholesterolemia
* age 18-60 years
* on statin treatment for at least 12 months

Exclusion Criteria:

* pregnancy or planned pregnancy
* breast feeding
* cancer
* non-compliance
* PUFA/omega-3 \< 3 months before inclusion

Primary outcomes:
measure: Reactive Hyperemia Index (RHI)
timeFrame: Baseline
measure: Reactive Hyperemia Index (RHI)
timeFrame: 3 months
measure: Reactive Hyperemia Index (RHI)
timeFrame: 6 months
measure: Reactive Hyperemia Index (RHI)
timeFrame: 9 months
Secondary outcomes:
measure: Markers of inflammation
timeFrame: Baseline
measure: Inflammatory markers
timeFrame: 3 months
measure: Inflammatory markers
timeFrame: 6 months
measure: Inflammatory markers
timeFrame: 9 months
Other outcomes:
measure: Lipid parameters
timeFrame: Baseline
measure: Lipid parameters
timeFrame: 3 months
measure: Lipid parameters
timeFrame: 6 months
measure: Lipid parameters
timeFrame: 9 months
Locations:
city: Bodø
country: Norway
facility: Division of Internal Medicine, Nordland Hospital
Study officials:
affiliation: Nordland Hospital
name: Knut T Lappegård, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02113306: Does Transcutaneous Vagal Nerve Stimulation Improves Fear Extinction in Humans
Official title: Does Transcutaneous Vagal Nerve Stimulation Improves Fear Extinction in Humans
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Healthy Adults
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
Collaborators: name: KU Leuven
First posted: 2014-04-14
Enrollment: 50
Sex: ALL
Minimum age (years): 16
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: A recent study with rats showed that electrical stimulation of the vagus nerve (VNS) facilitates extinction of fear (Pena, Engineer, \& McIntyre, Biological Psychiatry, 2013). The hypothesized mechanism is that VNS both enhances memory consolidation (by increasing noradrenergic neurotransmission) and reduces anxiety (thus: preventing fear responses to the CS which may re-consolidate the fear memory). The effect was only apparent when VNS occurred during exposure of the fear conditioned stimulus (CS), and not when stimulation was given immediately following exposure. These results may have implications for the treatment of anxiety disorders in humans. However, until recently, the only means to investigate the effects of VNS on human fear learning would have required the invasive implantation of vagus nerve stimulators. This has fortunately changed, as a non-invasive transcutaneous VNS device has been approved for use in the E.U. for the treatment of psychological disorders.

This study proposes to use a t-VNS to investigate its effects on fear learning and extinction in (healthy) humans. Previous research has only investigated the effects it has on human mood and memory. The results obtained suggest that it reduces negative affect and enhances memory, findings which are consistent with those reported for rats. It is thus reasonable to expect that t-VNS will facilitate the extinction of fear in humans.

The present study aims to answer the following research questions:

Does t-VNS during extinction training:

1. accelerates extinction curves
2. reduces spontaneous recovery of previously extinguished fear
3. reduce re-acquisition of fear
4. reduce generalization of fear to other stimuli that resemble the CS+?
5. facilitates the generalization of inhibitory learning to stimuli that resemble the CS-?


Eligibility criteria: Inclusion Criteria:

* healthy men and women aged 16 - 50 years

Exclusion Criteria:

* current or past psychiatric or neurological disorder
* use of psychopharmaca
* use of medication that affects autonomic nervous functioning (e.g., bèta-blockers)
* current cardiac or respiratory disorder
* pregnancy

Primary outcomes:
measure: fear response
timeFrame: 3 test days
Secondary outcomes:
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: Faculty of Psychology and Educational Science
Study officials:
affiliation: KU Leuven
name: Ilse Van Diest, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00873106: Retinal Thickness and Volume Estimates Given by Time Domain and Spectral Optical Coherence Tomography
Official title: Retinal Thickness and Volume Estimates Given by Time Domain and Spectral Optical Coherence Tomography
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Diabetic Maculopathy
Lead sponsor: Glostrup University Hospital, Copenhagen
Sponsor class: OTHER
First posted: 2009-04-01
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A group of diabetic and healthy participants

Brief summary: The purpose of the present study is to determine if the retinal thickness estimates of the Stratus OCT, the 3D OCT-1000, and the CirrusHD OCT are comparable in diabetic and in healthy individuals (OCT=Optical Coherence Tomography).


Eligibility criteria: Inclusion Criteria:

* diabetic retinopathy in the diabetic group
* healthy retinas in the healthy group

Exclusion Criteria:

* not able to cooperate
* retinal disease other than macular oedema
* severe media opacities (e.g. cataract)
* prior macular laser photocoagulation except for large oedemas

Primary outcomes:
measure: Retinal thickness and retinal volume from each OCT scan
timeFrame: within 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Glostrup
country: Denmark
facility: Department of Ophthalmology, Glostrup Hospital, University of Copenhagen, Nordre Ringvej 57
state: Copenhagen
Study officials:
affiliation: Department of Ophthalmology, Glostrup Hospital, University of Copenhagen, Nordre Ringvej 57, DK-2600 Glostrup, Denmark
name: Dorte Nellemann Thornit, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00828906: DuoTrav® Eye Drops As Replacement Therapy Program
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Open-angle Glaucoma
Ocular Hypertension
Keywords: Glaucoma
IOP
DuoTrav
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2009-01-26
Enrollment: 128
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the effectiveness of DuoTrav Eye Drops in gaining or maintaining control of target Intraocular Pressures (tIOP) in patients diagnosed with, and being treated for, open-angle glaucoma (OAG) or ocular hypertension (OH).


Eligibility criteria: Inclusion Criteria:

* Patients with OAG or OH for whom single agent therapy provides insufficient intraocular pressure reduction

Exclusion Criteria:

* None

Primary outcomes:
measure: Intra Ocular Pressure
timeFrame: visit 1, Visits 2-3, Visits 6-8
Secondary outcomes:
Other outcomes:
Locations:
city: Bejing
country: China
facility: Contact Alcon for Trial Locations
Study officials:
References: